ASCO: A new study highlights workplace discrimination reported by internationally trained female oncologists. Dr. Coral Olazagasti will present study findings that showed female oncologists reported much higher levels of gender or race/ethnicity-based discrimination than their male counterparts.
ASCO: Treatment options for multiple myeloma are shifting rapidly, with new patients increasingly being treated with a 4-part drug combination that includes a new immunotherapy agent. What does this mean for patients, and how will treatment change in the future?
AT ASCO: A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors.
Researchers from Penn Medicine’s Abramson Cancer Center (ACC) and the Perelman School of Medicine at the University of Pennsylvania will present data on the latest advances in cancer research at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, happening May 31—June 4, 2024 in Chicago and online.
A brief roundup of news and story ideas from the experts at UCLA Health.
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant.
Cancer drugs capable of weakening the body’s immune defenses are no more likely to increase the risk of Covid-19 infection or death than breast cancer therapies that do not undermine the immune system, a new study shows.
During the peak of the COVID-19 pandemic, several elective surgeries for renal cell carcinoma, the most common type of kidney cancer, were delayed with unknown impact on outcomes for patients. Researchers at Rutgers Cancer Institute of New Jersey explored the impact of surgery delays for these patients throughout the United States by utilizing the National Cancer Database to explore outcomes of patients who underwent surgery up to and after three months post diagnosis.
Dylan Graetz, M.D., M.P.H., a pediatric hematology-oncology fellow at St. Jude, has received a Young Investigator Award from the American Society of Clinical Oncology.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right